相关实验视频

Updated: May 8, 2025

In Vitro Imaging and Quantification of the Drug Targeting Efficiency of Fluorescently Labeled GnRH Analogues

In Vitro Imaging and Quantification of the Drug Targeting Efficiency of Fluorescently Labeled GnRH Analogues

Published on: March 21, 2017

两个GnRH-mitoxantrone结合物,Con-3和Con-7,向子宫内膜癌细胞

Christos Markatos¹, Georgia Biniari², Vlasios Karageorgos¹

¹Department of Pharmacology, School of Medicine, University of Crete, Heraklion, Greece.

Current molecular pharmacology

|February 4, 2025

概括

新的GnRH类似物Con-3和Con-7有效地将细胞毒性线粒激素传递给子宫内膜癌细胞,作为向前体药物显示出希望. 这些药物诱导了亡并减少了扩散,提供了一种新的治疗策略.

科学领域:

妇科瘤学妇科瘤学
癌症治疗方法癌症治疗方法
药物输送系统药物输送系统

背景情况:

子宫内膜癌是一种常见的妇科恶性瘤.
子宫内膜癌细胞表达性腺激素释放激素受体 (GnRH-R).
现有的GnRH-doxorubicin结合物容易受到血酶过早释放的药物影响.

研究的目的:

评估新型GnRH类似物Con-3和Con-7对子宫内膜癌细胞的细胞毒性.
通过通过细胞硫素减少二硫酸结合物释放的向药物释放机制的研究.
确定Con-3和Con-7作为用于治疗子宫内膜癌的新一类GnRH-R特异性前药物的潜力.

主要方法:

通过二硫化键将GnRH类似物与米托克桑结合,形成Con-3和Con-7.
用Con-3,Con-7和自由线粒激素治疗石川子宫内膜癌细胞.
使用剂量和时间依赖性测定评估细胞亡和增殖.
确定半最大抑制度 (IC50).

主要成果:

Con-3和Con-7在石川细胞上表现出剂量和时间依赖的细胞毒性作用.
对于Con-3和Con-7的IC50值在0.64至1.45μM之间,与自由的线粒激素相当.
通过细胞中介的硫化物键的减少,细胞成功地在癌细胞内释放了米托克桑.

结论:

Con-3和Con-7对子宫内膜癌细胞具有显著的抗癌活性.
双硫化物键连接确保了托克桑的向输送和释放,克服了以基结合物的局限性.
这些GnRH-mitoxantrone结合体代表了开发向子宫内膜癌治疗的有前途的新策略.

关键词:

抗癌药物抗癌药物抗癌药物这是子宫内膜癌的癌症.释放性激素释放性激素 (GONADOTROPIN) 是一种释放性激素.米托克桑. 米托克桑.接收器接收器接收器

更多相关视频

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...